ערך בספרים למניה: Kamada Ltd. (KMDA)

The share price retrospective for Kamada Ltd. (KMDA) demonstrates the dynamics of a company developing therapies for orphan diseases. The current figure stands at 4.66, supported by growth in plasma protein sales and the expansion of antidotes in the US. Business revenues are based on the sale of Glassia protein and specific vaccines. High cash flow resilience is ensured by the inelastic demand from patients for life-saving therapy.

Kamada Ltd. is strengthening its technological edge through robotic plasma fractionation, which reduces operational risks and capitalizes on tangible assets. By analyzing the book value per share, an investor determines the liquidation value of the business, comparing net assets with the market price to identify undervaluation or excessive premiums, which forms a long-term consensus regarding the company's fundamental stability.